These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 32955825

  • 1. Current strategies for detection and approach to measurable residual disease in acute myeloid leukemia.
    Palmieri R, Buccisano F, Maurillo L, Del Principe MI, Paterno G, Venditti A, Martinelli G, Cerchione C.
    Minerva Med; 2020 Oct; 111(5):386-394. PubMed ID: 32955825
    [Abstract] [Full Text] [Related]

  • 2. Role of minimal residual disease in the management of acute myeloid leukemia-a case-based discussion.
    Coltoff A, Houldsworth J, Keyzner A, Renteria AS, Mascarenhas J.
    Ann Hematol; 2018 Jul; 97(7):1155-1167. PubMed ID: 29704019
    [Abstract] [Full Text] [Related]

  • 3. Significance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes.
    Yalniz FF, Patel KP, Bashir Q, Marin D, Ahmed S, Alousi AM, Chen J, Ciurea SO, Rezvani K, Popat UR, Shpall EJ, Champlin RE, Oran B.
    Cancer; 2020 May 15; 126(10):2183-2192. PubMed ID: 32101640
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Fusion-harboring mast cells can explain molecular positivity in flow cytometric MRD-negative core-binding factor AML.
    Cook JA, Lott L, Perry J, Eckel AM, Xu D, Hudson CA, Wells DA, Loken MR, Menssen AJ.
    Blood; 2024 Aug 01; 144(5):581-585. PubMed ID: 38749014
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Quantitation of minimal residual disease in t(8;21)-positive acute myelogenous leukemia patients using real-time quantitative RT-PCR.
    Sugimoto T, Das H, Imoto S, Murayama T, Gomyo H, Chakraborty S, Taniguchi R, Isobe T, Nakagawa T, Nishimura R, Koizumi T.
    Am J Hematol; 2000 Jun 01; 64(2):101-6. PubMed ID: 10814988
    [Abstract] [Full Text] [Related]

  • 12. Prognostic Role of Postinduction Minimal Residual Disease and Myeloid Sarcoma Type Extramedullary Involvement in Pediatric RUNX1-RUNX1T1 (+) Acute Myeloid Leukemia.
    Lee JW, Kim S, Jang PS, Chung NG, Cho B, Im SA, Kim M.
    J Pediatr Hematol Oncol; 2020 Apr 01; 42(3):e132-e139. PubMed ID: 31688618
    [Abstract] [Full Text] [Related]

  • 13. High prognostic value of minimal residual disease detected by flow-cytometry-enhanced fluorescence in situ hybridization in core-binding factor acute myeloid leukemia (CBF-AML).
    Wang L, Gao L, Xu S, Gong S, Liu M, Qiu H, Xu X, Ni X, Chen L, Lu S, Chen J, Song X, Zhang W, Yang J, Hu X, Wang J.
    Ann Hematol; 2014 Oct 01; 93(10):1685-94. PubMed ID: 24844781
    [Abstract] [Full Text] [Related]

  • 14. Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation.
    Qin YZ, Wang Y, Zhu HH, Gale RP, Zhang MJ, Jiang Q, Jiang H, Xu LP, Chen H, Zhang XH, Liu YR, Lai YY, Jiang B, Liu KY, Huang XJ.
    Chin J Cancer; 2016 May 19; 35():46. PubMed ID: 27197573
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Minimal residual disease in acute myelogenous leukemia with PML/RAR alpha or AML1/ETO mRNA and phenotypic analysis of possible T and natural killer cells in bone marrow.
    Inokuchi K, Iwakiri R, Futaki M, Hanawa H, Tanosaki S, Nomura T, Dan K.
    Leuk Lymphoma; 1998 May 19; 29(5-6):553-61. PubMed ID: 9643569
    [Abstract] [Full Text] [Related]

  • 17. High aldehyde dehydrogenase activity at diagnosis predicts relapse in patients with t(8;21) acute myeloid leukemia.
    Yang L, Chen WM, Dao FT, Zhang YH, Wang YZ, Chang Y, Liu YR, Jiang Q, Zhang XH, Liu KY, Huang XJ, Qin YZ.
    Cancer Med; 2019 Sep 19; 8(12):5459-5467. PubMed ID: 31364309
    [Abstract] [Full Text] [Related]

  • 18. Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias.
    Krauter J, Gorlich K, Ottmann O, Lubbert M, Dohner H, Heit W, Kanz L, Ganser A, Heil G.
    J Clin Oncol; 2003 Dec 01; 21(23):4413-22. PubMed ID: 14645432
    [Abstract] [Full Text] [Related]

  • 19. Minimal/Measurable Residual Disease Monitoring in NPM1-Mutated Acute Myeloid Leukemia: A Clinical Viewpoint and Perspectives.
    Forghieri F, Comoli P, Marasca R, Potenza L, Luppi M.
    Int J Mol Sci; 2018 Nov 06; 19(11):. PubMed ID: 30404199
    [Abstract] [Full Text] [Related]

  • 20. Optimal Measurable Residual Disease Testing for Acute Myeloid Leukemia.
    Xiao W, Petrova-Drus K, Roshal M.
    Surg Pathol Clin; 2019 Sep 06; 12(3):671-686. PubMed ID: 31352980
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.